US$ 21.33
glp 1 negative effects The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Why do patients stop GLP-1
Description
Swallowing a supplement is so 2024

Trulicity (dulaglutide) Disease area(s): Metabolic diseases Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $5.25 billion Why it sold so well: In 2024, Eli Lillys Trulicity experienced a decline in sales, primarily due to increased competition and market dynamics

[DOI] [PubMed] [Google Scholar] 7.Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al

*Correspondence: Jonathan D
